Reading the tape
NASDAQ: MTSR
Metsera, Inc.
Healthcare · Biotechnology
Market Cap
$7.43B
52w High
$83.86
52w Low
$12.30
P/E
-23.55
Volume
27.87M
Outstanding Shares
105.38M
Not enough data to analyse price vs. fundamentals for this ticker.
Company profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
CEOChristopher Whitten Bernard
SectorHealthcare
IndustryBiotechnology
Employees93
IPO dateJan 31, 2025
Valuation
Forward P/E—
EV/EBITDA-10.94
Enterprise value$2.39B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-72.78%▼51.86%vs FY2023
Analyst consensus
RatingBuy
Target price$55.50▼21.28%
3
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 25, 2026
Q1 FY26 · EPS est -$0.54 · Revenue est —
View